

Are expensive vaccines the best investment in lower-middle income countries?

Simonsen, Lone; Wijhe, Maarten van; Taylor, Robert J.

Published in:
The Lancet Global Health

DOI:
[10.1016/S2214-109X\(19\)30040-3](https://doi.org/10.1016/S2214-109X(19)30040-3)

Publication date:
2019

Document Version
Publisher's PDF, also known as Version of record

Citation for published version (APA):
Simonsen, L., Wijhe, M. V., & Taylor, R. J. (2019). Are expensive vaccines the best investment in lower-middle income countries? *The Lancet Global Health*, 7(5), E548-E549. [https://doi.org/10.1016/S2214-109X\(19\)30040-3](https://doi.org/10.1016/S2214-109X(19)30040-3)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.

Take down policy

If you believe that this document breaches copyright please contact rucforsk@ruc.dk providing details, and we will remove access to the work immediately and investigate your claim.

Are expensive vaccines the best investment in low-income and middle-income countries?



See [Articles](#) page e644

In a new study in *The Lancet Global Health*, John Ojal and colleagues¹ project that the use of ten-valent pneumococcal conjugate vaccine (PCV10) will be cost-effective in Kenya after international donor support for vaccine programmes ends in around 2027. Until now, Kenya has relied on funding from Gavi, the international vaccine alliance, to fund its PCV programme. But because Gavi withdraws support from countries as their economies grow, Kenya will have to bear the full \$9 per child cost for a three-dose course of PCVs starting in 2027. For Kenya, where annual per capita actual expenditure for health is around \$70 (about 5% of GDP), that is not a trivial cost.²

Kenya is not alone in having to decide whether expensive vaccines are worth the money, as many other lower-middle-income countries with growing economies will soon lose international support. For these countries, careful evaluation of the cost-effectiveness and affordability of such programmes, and how they hold up against alternative investments in population health, are essential.³ The current study is a much-appreciated effort to provide important insights to countries around the world as they struggle to decide how best to spend scarce resources.

In their study, Ojal and colleagues used a sophisticated age-structured dynamic disease model to project the costs and benefits of continuing the Kenya PCV10 vaccine programme between 2022 and 2032, compared with letting the programme lapse.¹ The model relied on pneumococcal surveillance, case incidence, and case fatality data for invasive pneumococcal disease (IPD) and severe pneumonia from a large hospital in Kifili. The model accounted for serotype replacement and assessed both direct and indirect vaccine benefits, such as those for older children and seniors. The researchers noted that in 2032, the PCV programme would cost about \$150 for every disability-adjusted life-year (DALY) it averts, and have an annual programme cost of about \$18 million.

The researchers applied an often-used criterion for cost-effectiveness: is the cost per DALY averted less than the per-capita GDP?⁴ Given that Kenya's per-capita GDP in 2016 was \$1455, the estimate is easily under the threshold. Ojal and colleagues note that other relatively

expensive childhood vaccines such as *Haemophilus influenzae* type b (Hib) vaccine (\$85 per DALY averted) and rotavirus vaccine (\$200–400 per DALY averted, depending on the vaccine used), are similarly cost effective.¹

Importantly, in view of the fact that only 2% of the DALYs averted come from prevention of morbidity, the researchers' assessment of cost-effectiveness of PCV in Kenya was based almost entirely on the vaccine's ability to prevent deaths.¹ Their model relies on reasonable assumptions for the incidence of IPD, the ratio of IPD to pneumonia, the case fatality ratios, and other parameters. However, the degree to which PCV use actually reduces pneumococcal mortality in Kenya, or in any setting, is not well studied and far from clear.⁵ An often-cited randomised trial in the Gambia reported a 16% reduction in all-cause mortality among vaccinated children,⁶ but this was a secondary endpoint with a wide confidence interval. Findings of several studies have convincingly documented a significant reduction in IPD and pneumonia incidence, although serotype replacement can erode PCV benefits over time.⁷ However, very few studies have reported on the vaccine's effect on mortality. Results of one recent observational study showed that after PCV10 was introduced in Brazil in 2010, the vaccine caused pneumonia mortality to fall by about 10% nationally by 2014, with larger reductions in strata with lower socioeconomic status.⁵

Another important point is that pneumonia claims far more lives than IPD, and pneumonia mortality in Kenya and other lower-income countries was falling steadily long before the PCV programmes started.^{5,8,9} Indeed, teasing vaccine benefits from a background mortality that is rapidly decreasing due to other factors is a difficult modelling challenge. Many factors surely contributed to the decrease, such as better access to health care (especially antibiotics), improved nutrition, better housing, and hygiene.¹⁰ It is worth asking whether the funds needed to keep the PCV programme going would be better spent on non-vaccine programmes that address these factors.

Getting a clear view of mortality benefits of vaccination is not straightforward in any setting, but

it is especially difficult in countries that lack national vital statistics data. Nonetheless, more studies of the mortality benefits of vaccinations in Gavi-transitioning countries are sorely needed, especially when, as in the current study, the perceived cost effectiveness relies almost entirely on the vaccine's mortality benefits.

As lower-income countries continue to grow economically, improvements in pneumococcal mortality will probably continue, whether PCV is part of the solution or not. Against that background, these countries must decide whether they can afford the substantial costs of PCV, as well as other new and expensive vaccines. What is needed is a comprehensive evaluation of the affordability and mortality benefits that takes into consideration the dramatic increase in costs for childhood vaccine programmes, as well as creative thinking about what else that money could buy in lower-income countries. No one should doubt that vaccines are powerful tools, but that does not mean that they are always the tool to reach for first.

*Lone Simonsen, Maarten van Wijhe, Robert Taylor
 Department of Science and Environment, Roskilde University,
 Denmark (LS, MvW); and Sage Analytica, Portland, ME, USA (RT)
 lonesimo@ruc.dk

We declare no competing interests.

Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

- 1 Ojal J, Griffiths U, Hammit LL, et al. Sustaining pneumococcal vaccination after transitioning from Gavi support: a modelling and cost-effectiveness study in Kenya. *Lancet Glob Health* 2019; **7**: e646–56.
- 2 World Bank. World Development Indicators. Available from <https://databank.worldbank.org/data/reports.aspx?source=World-Development-Indicators> (accessed on Dec 23, 2018).
- 3 Cohen O, Muralidharan K, Gorham K, et al. Gap analysis of PCV impact evaluations in settings of routine use. 2017. https://www.jhspu.edu/ivac/wp-content/uploads/2018/05/PCVImpactAnalysis_PublicVersion_2017feb28.pdf (accessed Dec 23, 2018)
- 4 Bertram MY, Lauer JA, De Joncheere K, et al. Cost-effectiveness thresholds: pros and cons. *Bull World Health Organ* 2016; **94**: 925–30.
- 5 Schuck-Paim C, Taylor RJ, Alonso WJ, Weinberger DM, Simonsen L. Effect of pneumococcal conjugate vaccine introduction on childhood pneumonia mortality in Brazil: a retrospective observational study. *Lancet Glob Health* 2019; **7**: e249–56.
- 6 Cutts FT, Zaman SM, Enwere G. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial. *Lancet* 2005; **365**: 1139–46.
- 7 Feikin DR, Kagucia EW, Loo JD, et al. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. *PLoS Med* 2013; **10**: e1001517.
- 8 Institute for Health Metrics and Evaluation (IHME). GBD Compare. Seattle, WA: IHME, University of Washington, 2018. <http://vizhub.healthdata.org/gbd-compare> (accessed Dec 23, 2018)
- 9 WHO. Pneumococcal Conjugate Vaccine (PCV) Review of Impact Evidence (PRIME) summary of findings from systematic review. October 2017. https://www.who.int/immunization/sage/meetings/2017/october/3_FULL_PRIME_REPORT_2017Sep26.pdf (accessed Dec 23, 2018).
- 10 Hanf M, Nacher M, Guihenneuc C, Tubert-Bitter P, Chavance M. Global determinants of mortality in under 5s: 10 year worldwide longitudinal study. *BMJ* 2013; **347**: f6427.